Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294991 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2L3MBTL1GLAHTTTSHR | |
| SCHEMBL2418238 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2L3MBTL1GLAHTTTSHR | |
| SCHEMBL3753324 | 0.83 | L3MBTL1 (0.64) | SMN1; SMN2L3MBTL1GLAHTTTSHR | |
| SCHEMBL27645893 | 0.81 | ATM (0.48) | SMN1; SMN2L3MBTL1HTTPOLBALDH1A1 | |
| SCHEMBL13522679 | 0.81 | L3MBTL1 (0.61) | SMN1; SMN2L3MBTL1GLAHTTTSHR | |
| SCHEMBL13201957 | 0.80 | L3MBTL1 (0.52) | SMN1; SMN2L3MBTL1GLAHTTTSHR | |
| SCHEMBL7341605 | 0.79 | L3MBTL1 (0.55) | SMN1; SMN2L3MBTL1GLAHTTTSHR | |
| Hydrochloric Acid SCHEMBL1822813 | 0.78 | L3MBTL1 (0.50) | SMN1; SMN2L3MBTL1GLAHTTTSHR | |
| SCHEMBL7380670 | 0.77 | L3MBTL1 (0.57) | SMN1; SMN2L3MBTL1GLAHTTTSHR | |
| SCHEMBL14930159 | 0.77 | LMNA (0.59) | SMN1; SMN2L3MBTL1GLAHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867803-B2 | IRE-1α inhibitors | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-11-16 | — | — | US | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141424-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | SMN1; SMN2 952/4885L3MBTL1 586/4885GLA 2888/4885 |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | SMN1; SMN2 952/4885L3MBTL1 586/4885GLA 2888/4885 |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | SMN1; SMN2 657/4885L3MBTL1 525/4885GLA 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.